Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 3/20 | 1.00 |
| ▸ | CPT1A | P50416 | 3/20 | 1.00 |
| ▸ | CPT1B | Q92523 | 3/20 | 1.00 |
| ▸ | CRAT | P43155 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teglicar SCHEMBL4450575 | 1.00 | CPT2 (1.00) | CPT2CPT1ACPT1BCRAT | |
| Teglicar SCHEMBL3687135 | 1.00 | CPT2 (1.00) | CPT2CPT1ACPT1BCRAT | |
| SCHEMBL2912378 | 1.00 | CPT2 (1.00) | CPT2CPT1ACPT1BCRAT | |
| SCHEMBL2453804 | 0.93 | CPT2 (0.86) | CPT2CPT1ACPT1B | |
| SCHEMBL1579627 | 0.93 | CPT2 (0.86) | CPT2CPT1ACPT1B | |
| Formic Acid SCHEMBL2454365 | 0.89 | CPT2 (0.78) | CPT2CPT1ACPT1B | |
| SCHEMBL6760579 | 0.88 | CPT2 (0.78) | CPT2CPT1ACPT1B | |
| Teglicar SCHEMBL13568151 | 0.87 | CPT2 (0.78) | CPT2CPT1ACPT1B | |
| SCHEMBL12304907 | 0.87 | CPT2 (0.78) | CPT2CPT1ACPT1B | |
| SCHEMBL12304895 | 0.87 | CPT2 (0.78) | CPT2CPT1ACPT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250297321-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | INST NAT SANTE RECH MED (FR) | 2025-09-25 | — | — | US | claimed |
| CN-119607211-A | Application of CPT1A inhibitor in preparation of drugs for inhibiting melanoma metastasis | 南方科技大学 | 2025-03-14 | — | — | CN | claimed |
| EP-4469602-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | Université Paris Cité (FR) | 2024-12-04 | — | — | EP | claimed |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | claimed |
| EP-3687507-B1 | FUNCTIONALIZED POLYMERS FOR THE INTRACELLULAR RELEASE OF BIOACTIVE MOLECULES | SUNYAMED S R L (IT) | 2023-11-22 | — | — | EP | claimed |
| WO-2022212568-A9 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2023-11-16 | — | — | WO | claimed |
| WO-2023144357-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | UNIVERSITE PARIS CITE (FR) | 2023-08-03 | — | — | WO | claimed |
| EP-4219764-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | Université Paris Cité (FR) | 2023-08-02 | — | — | EP | claimed |
| WO-2022212568-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | WO | claimed |
| US-7705016-B2 | Regulation of food intake by modulation of long-chain fatty acyl-CoA levels in the hypothalamus | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-04-27 | — | — | US | claimed |
| US-20090131515-A1 | Combination of antidiabetic drugs | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-05-21 | — | — | US | claimed |
| EP-1592417-B1 | COMBINATION OF ANTIDIABETIC DRUGS | SIGMA TAU IND FARMACEUTI (IT) | 2007-04-18 | — | — | EP | claimed |
| US-20060058385-A1 | Combination of antidiabetic drugs | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-03-16 | — | — | US | claimed |
| EP-1592417-A1 | COMBINATION OF ANTIDIABETIC DRUGS | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2005-11-09 | — | — | EP | claimed |
| WO-2004069239-A1 | COMBINATION OF ANTIDIABETIC DRUGS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-08-19 | — | — | WO | claimed |
| EP-4658641-A1 | NOVEL COMPOUNDS THAT CAN BE USED AS THERAPEUTIC AGENTS | Xeniom GmbH (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250297321-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | INST NAT SANTE RECH MED (FR) | 2025-09-25 | — | — | US | disclosed |
| WO-2004069239-A1 | COMBINATION OF ANTIDIABETIC DRUGS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-08-19 | — | — | WO | disclosed |
| EP-1409448-A1 | PROCESS FOR THE PREPARATION OF (R)- OR (S)-AMINOCARNITINE INNER SALT, THE SALTS AND DERIVATIVES THEREOF | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010129-A1 | PROCESS FOR THE PREPARATION OF (R)- OR (S)-AMINOCARNITINE INNER SALT, THE SALTS AND DERIVATIVES THEREOF | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | CPT2 1/4885CPT1A 15/4885CPT1B 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.